Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights.

Shokoohian, B; Negahdari, B; Aboulkheyr Es, H; Abedi-Valugerdi, M; Baghaei, K; Agarwal, T; Maiti, TK; Hassan, M; Najimi, M; Vosough, M

Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights.

Shokoohian, B Negahdari, B Aboulkheyr Es, H Abedi-Valugerdi, M Baghaei, K Agarwal, T Maiti, TK Hassan, M Najimi, M Vosough, M

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: J Cell Mol Med, 2021, 25, (18), pp. 8602-8614
Issue Date:: 2021-09

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.08 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Shokoohian, B
dc.contributor.author	Negahdari, B
dc.contributor.author	Aboulkheyr Es, H
dc.contributor.author	Abedi-Valugerdi, M
dc.contributor.author	Baghaei, K
dc.contributor.author	Agarwal, T
dc.contributor.author	Maiti, TK
dc.contributor.author	Hassan, M
dc.contributor.author	Najimi, M
dc.contributor.author	Vosough, M
dc.date.accessioned	2022-03-09T06:06:02Z
dc.date.available	2021-08-04
dc.date.available	2022-03-09T06:06:02Z
dc.date.issued	2021-09
dc.identifier.citation	J Cell Mol Med, 2021, 25, (18), pp. 8602-8614
dc.identifier.issn	1582-1838
dc.identifier.issn	1582-4934
dc.identifier.uri	http://hdl.handle.net/10453/155105
dc.description.abstract	Hepatocellular carcinoma (HCC), the most common type of liver cancer, is usually a latent and asymptomatic malignancy caused by different aetiologies, which is a result of various aberrant molecular heterogeneity and often diagnosed at advanced stages. The incidence and prevalence have significantly increased because of sedentary lifestyle, diabetes, chronic infection with hepatotropic viruses and exposure to aflatoxins. Due to advanced intra- or extrahepatic metastasis, recurrence is very common even after radical resection. In this paper, we highlighted novel therapeutic modalities, such as molecular-targeted therapies, targeted radionuclide therapies and epigenetic modification-based therapies. These topics are trending headlines and their combination with cell-based immunotherapies, and gene therapy has provided promising prospects for the future of HCC treatment. Moreover, a comprehensive overview of current and advanced therapeutic approaches is discussed and the advantages and limitations of each strategy are described. Finally, very recent and approved novel combined therapies and their promising results in HCC treatment have been introduced.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	J Cell Mol Med
dc.relation.isbasedon	10.1111/jcmm.16875
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0304 Medicinal and Biomolecular Chemistry, 0601 Biochemistry and Cell Biology, 1103 Clinical Sciences
dc.subject.classification	Biochemistry & Molecular Biology
dc.subject.mesh	Animals
dc.subject.mesh	Carcinoma, Hepatocellular
dc.subject.mesh	Combined Modality Therapy
dc.subject.mesh	Humans
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Liver Neoplasms
dc.subject.mesh	Molecular Targeted Therapy
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Carcinoma, Hepatocellular
dc.subject.mesh	Liver Neoplasms
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Combined Modality Therapy
dc.subject.mesh	Molecular Targeted Therapy
dc.title	Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights.
dc.type	Journal Article
utslib.citation.volume	25
utslib.location.activity	England
utslib.for	0304 Medicinal and Biomolecular Chemistry
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1103 Clinical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
utslib.copyright.status	open_access	*
dc.date.updated	2022-03-09T06:05:58Z
pubs.issue	18
pubs.publication-status	Published
pubs.volume	25
utslib.citation.issue	18

Abstract:

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is usually a latent and asymptomatic malignancy caused by different aetiologies, which is a result of various aberrant molecular heterogeneity and often diagnosed at advanced stages. The incidence and prevalence have significantly increased because of sedentary lifestyle, diabetes, chronic infection with hepatotropic viruses and exposure to aflatoxins. Due to advanced intra- or extrahepatic metastasis, recurrence is very common even after radical resection. In this paper, we highlighted novel therapeutic modalities, such as molecular-targeted therapies, targeted radionuclide therapies and epigenetic modification-based therapies. These topics are trending headlines and their combination with cell-based immunotherapies, and gene therapy has provided promising prospects for the future of HCC treatment. Moreover, a comprehensive overview of current and advanced therapeutic approaches is discussed and the advantages and limitations of each strategy are described. Finally, very recent and approved novel combined therapies and their promising results in HCC treatment have been introduced.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/155105